11 hrs ago
Haemonetics Corp - 10-Q - Management's Discussion and Analysis of...
This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with both our interim consolidated financial statements and notes thereto which appear elsewhere in this Quarterly Report on Form 10-Q and our annual consolidated financial statements, notes thereto and the MD&A contained in our ... (more)
Tue Jul 29, 2014
Can Biogen Idec Take Wing With Tecfidera?
Biogen Idec generates most of its revenue from drugs for MS , but also receives substantial sums from other disease indications.
Biogen: The Pioneer In The Hemophilia A Market
Biogen received the FDA approval for its breakthrough drug, Eloctate. It is the second FDA approval following the authorization of its Hemophilia B therapy, Alprolix.
Wed Jul 23, 2014
Nine Chicago Nonprofits To Receive Almost $400,000 In Donations And...
Starlight Children's Foundation Midwest, dedicated to improving the lives and health of seriously ill children and their families, was the first place winner and will receive a .
Tue Jul 22, 2014
Patient safety concerns raised after nursing staff reduction at SJ hospital
Patients with bleeding disorders such as hemophilia say reductions to nursing staff at the Saint John Regional Hospital are putting their health at risk.
Why Ontario is moving to ban paying people for their blood
Ontario plans to join Quebec in banning payments to people for their blood and blood plasma, following the opening of two paid plasma clinics in Toronto.
Baxter Declares Quarterly Dividend
As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
Sat Jul 19, 2014
JAMA opinion piece calls for ending lifetime ban on blood donation by gay men
Gay marriage laws and court rulings against sexual-orientation discrimination are all signs that it's time for the federal government to change its blood-donor policy for gay and bisexual men, authors said in a commentary released Saturday.
Fri Jul 18, 2014
New Coagulation Factor Shows Promise as Once-Weekly Prophylaxis for Hemophilia B
Positive results have been reported from a phase III trial comparing a prophylactic regimen of BeneFIX coagulation factor IX, recombinant 100 IU/kg once-weekly with on-demand treatment in subjects with moderately severe to severe hemophilia B .
Biotech Enters Reporting Season With Large Caps Central To Sector Performance
Biotech stock stocks enter their earnings season with investors increasingly interested in the long-term outlook for product pipelines, although large-cap growth stocks remain central to the sectors performance, an analyst said Friday.
Thu Jul 17, 2014
UPDATE 1-Medical products boost Baxter's sales
Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly earnings and revenue, helped by surging sales in its medical products division.
Plant-based research improves hemophilia treatment
Hemophilia is a rare but potentially dangerous disease. People with the condition produce very low levels of clotting factor, the proteins in blood that stop bleeding and help begin the healing process.
Arcade pharmacy to add home health nursing services
Cottril's Pharmacy Inc. filed an application with the state Department of Health to become licensed as a home health services agency.
Wed Jul 16, 2014
Positive top-line results for BeneFIX
In a Phase 3 clinical tria l comparing Pfizer's BeneFIX Coagulation Factor IX as a treatment for patients with moderately severe-to-severe hemophilia B to on-demand treatment, the once-weekly therapy achieved its primary endpoint of a statistically significant reduction in the annualized bleeding rate versus on-demand.
Why Pfizer (PFE) Stock Is Up Today
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Pfizer says clotting drug's once-weekly dose reduces bleeding rate
Pfizer Inc said a once-weekly dose of its drug, already approved for on-demand treatment of a blood clotting disorder, reduced bleeding rates in patients in a late-stage study.
Pfizer Inc. Hemophilia B Treatment Regimen Meets Endpoint In Phase 3 Trial
Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA Once-Weekly Prophylaxis For Hemophilia B - See more at: http://press.pfizer.com/press-release/pfizer-announces-positive-top-line-results-phase-3-study-nonacog-alfa-benefix-once-wee#sthash.YaBu8KgQ.dpuf Once-Weekly Prophylaxis Treatment with BeneFIXA Significantly Reduced ... (more)
Wall Street Journal
Pfizer Hemophilia B Treatment Regimen Meets Endpoint
Pfizer Inc. said a regimen for treating patients with hemophilia B met the primary endpoint of its Phase 3 trial.
Fri Jul 11, 2014
Research and Markets: Global Blood Plasma Market Report: 2014 Edition
With the swift changes and advancement in biomedical/healthcare technology, the healthcare/pharmaceutical/therapeutic industry is becoming ever more competitive.
Wed Jul 09, 2014
Baxter Acquires AesRx, LLC, Including Its Investigational Sickle Cell Disease Treatment
Baxter International Inc. today announced the acquisition of AesRx, LLC, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease .